Middle East and Africa Cervical Cancer Diagnostic Testing Market

Historic Data: 2019-2020   |   Base Year: 2021   |   Forecast Period: 2022-2028

Analysis By Type (PAP Testing, HPV Testing, Colposcopy, Cervical Biopsies, Cystoscopy, and Others) and Service Provider (Diagnostics and Research Laboratories, Hospitals and Clinics, Specialty Clinics, and Home Care Services)     

No. of Pages: 127
Report Code: TIPRE00027458
Category: Life Sciences
Middle East and Africa Cervical Cancer Diagnostic Testing Market
Buy Now

The MEA cervical cancer diagnostic testing market is expected to grow from US$ 218.90 million in 2021 to US$ 282.38 million by 2028; it is estimated to grow at a CAGR of 3.7% from 2021 to 2028.

The cervical cancer diagnosis test market players focus on launching new products to expand their geographic reach and enhance capacities to cater to a greater than existing customer base. In November 2021, Hologic, Inc. launched the Genius Digital Diagnostics System for cervical cancer screening. Next-generation screening systems combine deep earning-based artificial intelligence (AI) with the latest volumetric imaging technology to assess precancerous lesions and cervical cancer cells in women. Similarly, in 2019, BD’s COR PX/GX system was launched, which is available in centralized labs across region since 2019 to assist in high-volume processing and increase overall efficiency. Similarly, one popular government insurance program provides cover for PAP tests, pelvic exams, and clinical breast examinations performed every two years for cervical cancer screening. Such programs and developments and launches of new products are likely to bring new trends in the MEA cervical cancer diagnosis test market in the coming years, thereby supporting its growth.

 

In case of COVID-19, MEA is highly affected especially South Africa. The healthcare sector in the UAE has undergone a considerable number of infrastructure and procedural changes to position itself as a leading healthcare provider. These improvements have been more recently recognized throughout the COVID-19 pandemic due to the continuous investments made to improve the sector’s hard and soft infrastructure. However, COVID-19 is likely to continue to have a notable impact on healthcare operations in countries. The pandemic had a major impact on a wide range of health outcomes. Disordering of elective health services related to cervical screening, management of abnormal screening test results, and treatment of pre-cancers, that lead to increase in cervical cancer incidence and inflame existing health disproportions. Since, the beginning of 2020, the pandemic has caused enormous health, social and economic impacts, likely to continue in 2021. Even after some of these impacts have been mitigated or contained, there will be medium and longer-term consequences. In many countries, diagnostics services have been disrupted, and supply chains for key commodities have been stretched. In Africa, COVID-19 has threatened the control of major health conditions including cervical cancer. As COVID-19 continues to spread in Africa, there are concerns over its impact on market, limited diagnosis, and decreased access to expert gynecologists further impacting the market in the region. However, as the pandemic situation overcomes, the demand for several diagnostics modalities used in cervical cancer diagnosis will increase. 

 

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the MEA cervical cancer diagnostic testing market. The MEA cervical cancer diagnostic testing market is expected to grow at a good CAGR during the forecast period. 

 

MEA Cervical Cancer Diagnostic Testing Market Revenue and Forecast to 2028 (US$ Million)     

MEA Cervical Cancer Diagnostic Testing Market Revenue and Forecast to 2028 (US$ Million)       

MEA Cervical Cancer Diagnostic Testing Market Segmentation 

MEA Cervical Cancer Diagnostic Testing Market – By Type

  • PAP Testing
  • HPV Testing
  • Colposcopy
  • Cervical Biopsies
  • Cystoscopy
  • Others

MEA Cervical Cancer Diagnostic Testing Market – By Service Provider

  • Diagnostics and Research Laboratories
  • Hospitals and Clinics
  • Specialty Clinics
  • Home Care Services

MEA Cervical Cancer Diagnostic Testing Market, by Country

  • South Africa
  • Saudi Arabia   
  • UAE 
  • Rest of MEA

MEA Cervical Cancer Diagnostic Testing Market - Companies Mentioned

  • Abbott
  • BD
  • Cooper Companies, Inc.
  • F. Hoffmann-La Roche Ltd.  
  • Femasys Inc.
  • Guided Therapeutics, Inc
  • Hologic, Inc.  
  • QIAGEN
  • Quest Diagnostics Incorporated   

Middle East and Africa Cervical Cancer Diagnostic Testing Market Strategic Insights

global-market-strategic-framework
Get more information on this report

Middle East and Africa Cervical Cancer Diagnostic Testing Market Segmentation Analysis

Middle East and Africa Cervical Cancer Diagnostic Testing Market Report Highlights

Middle East and Africa Cervical Cancer Diagnostic Testing Report Scope

Report Attribute Details
Market size in 2021 US$ 218.90 Million
Market Size by 2028 US$ 282.38 Million
CAGR (2021 - 2028) 3.7%
Historical Data 2019-2020
Forecast period 2022-2028
Segments Covered By Type
  • PAP Testing
  • HPV Testing
  • Colposcopy
  • Cervical Biopsies
  • Cystoscopy
By Service Provider
  • Diagnostics and Research Laboratories
  • Hospitals and Clinics
  • Specialty Clinics
  • Home Care Services
Regions and Countries Covered Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Abbott
  • BD
  • Cooper Companies, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Femasys Inc.
  • Guided Therapeutics, Inc
  • Hologic, Inc.
  • QIAGEN
  • Quest Diagnostics Incorporated
Get more information on this report

Middle East and Africa Cervical Cancer Diagnostic Testing Market Country and Regional Insights

middle-east-and-africacervical-cancer-diagnostic-testing-market
Get more information on this report
Identical Market Reports with other Region/Countries

The List of Companies - Middle East and Africa Cervical Cancer Diagnostic Testing Market

  1. Abbott
  2. BD
  3. Cooper Companies, Inc.
  4. F. Hoffmann-La Roche Ltd.
  5. Femasys Inc.
  6. Guided Therapeutics, Inc  
  7. Hologic, Inc.
  8. QIAGEN
  9. Quest Diagnostics Incorporated       
Frequently Asked Questions
How big is the Middle East and Africa Cervical Cancer Diagnostic Testing Market?

The Middle East and Africa Cervical Cancer Diagnostic Testing Market is valued at US$ 218.90 Million in 2021, it is projected to reach US$ 282.38 Million by 2028.

What is the CAGR for Middle East and Africa Cervical Cancer Diagnostic Testing Market by (2021 - 2028)?

As per our report Middle East and Africa Cervical Cancer Diagnostic Testing Market, the market size is valued at US$ 218.90 Million in 2021, projecting it to reach US$ 282.38 Million by 2028. This translates to a CAGR of approximately 3.7% during the forecast period.

What segments are covered in this report?

The Middle East and Africa Cervical Cancer Diagnostic Testing Market report typically cover these key segments-

  • Type (PAP Testing, HPV Testing, Colposcopy, Cervical Biopsies, Cystoscopy)
  • Service Provider (Diagnostics and Research Laboratories, Hospitals and Clinics, Specialty Clinics, Home Care Services)

What is the historic period, base year, and forecast period taken for Middle East and Africa Cervical Cancer Diagnostic Testing Market?

The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Middle East and Africa Cervical Cancer Diagnostic Testing Market report:

  • Historic Period : 2019-2020
  • Base Year : 2021
  • Forecast Period : 2022-2028
    • Who are the major players in Middle East and Africa Cervical Cancer Diagnostic Testing Market?

    The Middle East and Africa Cervical Cancer Diagnostic Testing Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Abbott
  • BD
  • Cooper Companies, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Femasys Inc.
  • Guided Therapeutics, Inc
  • Hologic, Inc.
  • QIAGEN
  • Quest Diagnostics Incorporated
    • Who should buy this report?

    The Middle East and Africa Cervical Cancer Diagnostic Testing Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Middle East and Africa Cervical Cancer Diagnostic Testing Market value chain can benefit from the information contained in a comprehensive market report.

    Available Report Formats

    pdf-format excel-format pptx-format
    Buy Now

    Customization Form

    Please tell us your area of interest
    (Market Segments/ Regions and Countries/ Companies)